Orina Belton

Orina Belton

Auto-generated profile, based on publicly available information

Orina Belton

School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2004 in Blood
Verified
Journal Article
Closed access
PDF file
JCJudith A. Coppinger
Judith A. Coppinger
GCGerard Cagney
Gerard Cagney
STSinead Toomey
Sinead Toomey
TKThomas Kislinger
Thomas Kislinger
OBOrina Belton
Orina Belton
PMPatricia B Maguire
Patricia B Maguire
Proteins secreted by activated platelets can adhere to the vessel wall and promote the development of atherosclerosis and thrombosis. Despite this biologic significance, however, the complement of proteins comprising the platelet releasate is largely unknown. Using a proteomics approach, we have identified more than 300 proteins released by human platelets following thrombin activation. Many of the proteins identified were not previously attributed to platelets, including secretogranin III, a potential monocyte chemoattractant precursor; cyclophilin A, a vascular smooth muscle cell growth factor; calumenin, an inhibitor of the vitamin K epoxide reductase-warfarin interaction, as well as proteins of unknown function that map to expressed sequence tags. Secretogranin III, cyclophilin A, and calumenin were confirmed to localize in platelets and to be released upon activation. Furthermore, while absent in normal vasculature, they were identified in human atherosclerotic lesions. Therefore, these and other proteins released from platelets may contribute to atherosclerosis and to the thrombosis that complicates the disease. Moreover, as soluble extracellular proteins, they may prove suitable as novel therapeutic targets.

22 August 2000 in Circulation
Verified
Journal Article
Closed access
PDF file
OBOrina Belton
Orina Belton
DBDara Byrne
Dara Byrne
DKDermot Kearney
Dermot Kearney
ALAustin Leahy
Austin Leahy
DFDesmond J. Fitzgerald
Desmond J. Fitzgerald
Background—The formation of prostacyclin (PGI2), thromboxane (TX) A2, and isoprostanes is markedly enhanced in atherosclerosis. We examined the relative contribution of cyclooxygenase (COX)-1 and -2 to the generation of these eicosanoids in patients with atherosclerosis.Methods and Results—The study population consisted of 42 patients with atherosclerosis who were undergoing surgical revascularization. COX-2 mRNA was detected in areas of atherosclerosis but not in normal blood vessel walls, and there was evidence of COX-1 induction. The use of immunohistochemical studies localized the COX-2 to proliferating vascular smooth muscle cells and macrophages. Twenty-four patients who did not previously receive aspirin were randomized to receive either no treatment or nimesulide at 24 hours before surgery and then for 3 days. Eighteen patients who were receiving aspirin were continued on a protocol of either aspirin alone or a combination of aspirin and nimesulide. Urinary levels of 11-dehydro-TXB2and 2,3-dinor-6-keto-PGF1α, metabolites of TXA2and PGI2, respectively, were elevated in patients with atherosclerosis compared with normal subjects (3211±533 versus 679±63 pg/mg creatinine,P<0.001; 594±156 versus 130±22 pg/mg creatinine,P<0.05, respectively), as was the level of the isoprostane 8-iso-PGF2α. Nimesulide reduced 2,3-dinor-6-keto-PGF1αexcretion by 46±5% (378.3±103 to 167±37 pg/mg creatinine,P<0.01) preoperatively and blunted the increase after surgery. Nimesulide had no significant effect on 11-dehydro-TXB2before (2678±694 to 2110±282 pg/mg creatinine) or after surgery. The levels of both products were lower in patients who were taking aspirin, and no further reduction was seen with the addition of nimesulide. None of the treatments influenced urinary 8-iso-PGF2αexcretion.Conclusions—Both COX-1 and -2 are expressed and contribute to the increase in PGI2in patients with atherosclerosis, whereas TXA2is generated by COX-1.

24 June 2011 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDMichelle M. Duffy
Michelle M. Duffy
JPJana Pindjakova
Jana Pindjakova
SHShirley A. Hanley
Shirley A. Hanley
CMCathal McCarthy
Cathal McCarthy
GWGudrun A. Weidhofer
Gudrun A. Weidhofer
Matthew GriffinMatthew Griffin
Matthew Griffin
Mesenchymal stem cells (MSCs) inhibit T‐cell activation and proliferation but their effects on individual T‐cell‐effector pathways and on memory versus naïve T cells remain unclear. MSC influence on the differentiation of naïve and memory CD4+ T cells toward the Th17 phenotype was examined. CD4+ T cells exposed to Th17‐skewing conditions exhibited reduced CD25 and IL‐17A expression following MSC co‐culture. Inhibition of IL‐17A production persisted upon re‐stimulation in the absence of MSCs. These effects were attenuated when cell–cell contact was prevented. Th17 cultures from highly purified naïve‐ and memory‐phenotype responders were similarly inhibited. Th17 inhibition by MSCs was reversed by indomethacin and a selective COX‐2 inhibitor. Media from MSC/Th17 co‐cultures contained increased prostaglandin E2 (PGE2) levels and potently suppressed Th17 differentiation in fresh cultures. MSC‐mediated Th17 inhibition was reversed by a selective EP4 antagonist and was mimicked by synthetic PGE2 and a selective EP4 agonist. Activation‐induced IL‐17A secretion by naturally occurring, effector‐memory Th17 cells from a urinary obstruction model was also inhibited by MSC co‐culture in a COX‐dependent manner. Overall, MSCs potently inhibit Th17 differentiation from naïve and memory T‐cell precursors and inhibit naturally‐occurring Th17 cells derived from a site of inflammation. Suppression entails cell‐contact‐dependent COX‐2 induction resulting in direct Th17 inhibition by PGE2 via EP4.

17 June 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SMSimone Marcone
Simone Marcone
OBOrina Belton
Orina Belton
DFDesmond J. Fitzgerald
Desmond J. Fitzgerald

19 July 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
MGMonica de Gaetano
Monica de Gaetano
DCDaniel Crean
Daniel Crean
MBMary Barry
Mary Barry
OBOrina Belton
Orina Belton
Atherosclerosis is an inflammatory disease caused by endothelial injury, lipid deposition and oxidative stress. This progressive disease can be converted into an acute clinical event by plaque rupture and thrombosis. In the context of atherosclerosis, the underlying cause of myocardial infarction and stroke, macrophages uniquely possess a dual functionality, regulating lipid accumulation and metabolism and sustaining the chronic inflammatory response, two of the most well documented pathways associated with the pathogenesis of the disease. Macrophages are heterogeneous cell populations and it is hypothesized that, during the pathogenesis of atherosclerosis, macrophages in the developing plaque can switch from a pro-inflammatory (MΦ1) to an anti-inflammatory (MΦ2) phenotype and vice versa, depending on the microenvironment. The aim of this study was to identify changes in macrophage subpopulations in the progression of human atherosclerotic disease. Established atherosclerotic plaques from symptomatic and asymptomatic patients with existing coronary artery disease undergoing carotid endarterectomy were recruited to the study. Comprehensive histological and immunohistochemical analyses were performed to quantify the cellular content and macrophage subsets of atherosclerotic lesion. In parallel, expression of MΦ1 and MΦ2 macrophage markers were analysed by real time-PCR and Western blot analysis. Gross analysis and histological staining demonstrated that symptomatic plaques presented greater haemorrhagic activity and the internal carotid was the most diseased segment, based on the predominant prevalence of fibrotic and necrotic tissue, calcifications and haemorrhagic events. Immunohistochemical analysis showed that both MΦ1 and MΦ2 macrophages are present in human plaques. However, MΦ2 macrophages are localised to more stable locations within the lesion. Importantly, gene and protein expression analysis of MΦ1/ MΦ2 markers evidenced that MΦ1 markers and Th1 associated cytokines are highly expressed in symptomatic plaques, whereas, expression of the MΦ2 markers, MR and CD163 and Th2 cytokines are inversely related with disease progression. This data increases the understanding of atherosclerosis development, identifying the cellular content of lesions during disease progression and characterising macrophage subpopulation within human atherosclerotic plaques.

9 May 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
EBEoin Brennan
Eoin Brennan
BWBo Wang
Bo Wang
AMAaron McClelland
Aaron McClelland
MMMuthukumar Mohan
Muthukumar Mohan
MMMariam Marai
Mariam Marai
PKPhillip Kantharidis
Phillip Kantharidis
The let-7 miRNA family plays a key role in modulating inflammatory responses. Vascular smooth muscle cell (SMC) proliferation and endothelial cell (EC) dysfunction are critical in the pathogenesis of atherosclerosis, including in the setting of diabetes. Here we report that let-7 levels are decreased in diabetic human carotid plaques and in a model of diabetes-associated atherosclerosis, the diabetic ApoE−/− mouse. In vitro platelet-derived growth factor (PDGF)– and tumor necrosis factor-α (TNF-α)–induced vascular SMC and EC activation was associated with reduced let-7 miRNA expression via Lin28b, a negative regulator of let-7 biogenesis. Ectopic overexpression of let-7 in SMCs inhibited inflammatory responses including proliferation, migration, monocyte adhesion, and nuclear factor-κB activation. The therapeutic potential of restoring let-7 levels using a let-7 mimic was tested: in vitro in SMCs using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model. Furthermore, we delivered let-7 mimic to human carotid plaque ex vivo and observed significant changes to the secretome in response to let-7 therapy. Restoration of let-7 expression could provide a new target for an anti-inflammatory approach in diabetic vascular disease.